Aurinia Pharmaceuticals (AUPH) PT Raised to $20 at RBC Capital Following 'Robust' Phase 3 Data
Tweet Send to a Friend
RBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $20.00 (from $11.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
